A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
出版年份 2023 全文链接
标题
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2023-10-29
DOI
10.1080/14740338.2023.2277801
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data
- (2022) Chunyan Wei et al. International Journal of Clinical Pharmacy
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections
- (2021) Ruwen Böhm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review
- (2021) Fabio A. Lievano et al. DRUG SAFETY
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
- (2021) Paolo F Caimi et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
- (2021) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia
- (2020) Eunice S. Wang et al. LEUKEMIA & LYMPHOMA
- FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
- (2020) Elaine Chang et al. CLINICAL CANCER RESEARCH
- Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
- (2020) S. Greten et al. JOURNAL OF NEURAL TRANSMISSION
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
- (2019) C. Kimberly Tsui et al. Nature Chemical Biology
- An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
- (2019) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
- (2018) Auayporn Nademanee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists
- (2018) Lars Mecklenburg TOXICOLOGIC PATHOLOGY
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- A curated and standardized adverse drug event resource to accelerate drug safety research
- (2016) Juan M. Banda et al. Scientific Data
- Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
- (2015) Robert Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™
- (2015) Ayako Suzuki et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
- (2014) Robert J. Fontana GASTROENTEROLOGY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
- (2013) Allen D. Brinker et al. DRUG SAFETY
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- LiverTox: A website on drug-induced liver injury
- (2012) Jay H. Hoofnagle et al. HEPATOLOGY
- Acute Liver Failure Due to Drugs
- (2008) Robert Fontana SEMINARS IN LIVER DISEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More